Akari Therapeutics (AKTX) Other Non-Current Liabilities (2014 - 2025)
Akari Therapeutics recorded quarterly Other Non-Current Liabilities of $230000.0 in Q4 2025, up 130.0% quarter-over-quarter from $100000.0 in Q3 2025, and down 39.95% year-over-year from $383000.0 in Q4 2024.
Akari Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $230000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 39.95% year-over-year to $230000.0; the TTM figure through Dec 2025 stood at $230000.0 (down 39.95% YoY), while the FY2025 annual figure was $230000.0, down 39.95% from the prior year.
- Other Non-Current Liabilities came in at $230000.0 for Q4 2025 at Akari Therapeutics, up from $100000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q2 2023 to a low of $100000.0 in Q4 2022.
- A 4-year average of $301071.8 and a median of $100000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 283.0% in 2024 and fell as far as 94.13% in 2024.
- Akari Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then jumped by 283.0% to $383000.0 in 2024, then sank by 39.95% to $230000.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $230000.0, $100000.0, and $128000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 128,000.00 |
| Mar 31, 2025 | 266,000.00 |
| Dec 31, 2024 | 383,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 100,000.00 |
| Dec 31, 2019 | 1,015.00 |
| Sep 30, 2018 | 156,844.00 |
| Jun 30, 2018 | 213,204.00 |
| Mar 31, 2018 | 94,325.00 |
| Dec 31, 2017 | 48.00 |
| Sep 30, 2017 | 53,095.00 |
| Jun 30, 2017 | 1,676.00 |
| Mar 31, 2017 | 57,198.00 |
| Dec 31, 2016 | 56.00 |
| Sep 30, 2016 | 55,522.00 |
| Jun 30, 2016 | 55,131.00 |
| Mar 31, 2016 | 3,031.00 |
| Dec 31, 2015 | 49.00 |
| Sep 30, 2015 | 439.00 |
| Mar 31, 2015 | 38,000.00 |
| Dec 31, 2014 | 33,000.00 |